Immix Biopharma (NASDAQ: IMMX) insider transactions
In the twelve months to 10 November 2026, executives and directors of Immix Biopharma reported 0 open-market sales and 2 open-market purchases of 1,516 shares ($10,042), by 2 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 22 May 2026 | Hsu Jason | Director | Grant or award | +6,250 | — | 899,250 | Form 4 |
| 22 May 2026 | Buchan Jane | Director | Grant or award | +6,250 | — | 28,705 | Form 4 |
| 22 May 2026 | Chudnovsky Yekaterina | Director | Grant or award | +6,250 | — | 6,250 | Form 4 |
| 22 May 2026 | Chang Nancy T | Director | Grant or award | +6,250 | — | 428,190 | Form 4 |
| 22 May 2026 | Marquet Magda | Director | Grant or award | +6,250 | — | 52,342 | Form 4 |
| 22 May 2026 | Adams Helen C. | Director | Grant or award | +6,250 | — | 181,004 | Form 4 |
| 22 May 2026 | Ng Carey | Director | Grant or award | +6,250 | — | 26,250 | Form 4 |
| 10 December 2025 | Morris Gabriel S | CFO | Open-market purchase | +770 | $6.58 | 291,429 | Form 4 |
| 10 December 2025 | Rachman Ilya M | CEO and Chairman | Open-market purchase | +746 | $6.67 | 1,141,683 | Form 4 |
| 8 December 2025 | Morris Gabriel S | CFO | Option exercise | +156,000 | $0.80 | 426,844 | Form 4 |
| 17 September 2025 | Rachman Ilya M | CEO and Chairman | Open-market purchase | +2,500 | $2.02 | 1,140,937 | Form 4 |
| 16 September 2025 | Morris Gabriel S | CFO | Open-market purchase | +2,600 | $1.97 | 290,659 | Form 4 |
| 18 June 2025 | Morris Gabriel S | CFO | Open-market purchase | +2,225 | $2.28 | 288,059 | Form 4 |
| 18 June 2025 | Rachman Ilya M | CEO and Chairman | Open-market purchase | +2,178 | $2.30 | 1,138,437 | Form 4 |
| 23 December 2024 | Hsu Jason | Director | Open-market purchase | +40,000 | $2.19 | 893,000 | Form 4 |
| 20 December 2024 | Hsu Jason | Director | Open-market purchase | +7,700 | $2.17 | 853,000 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Immix Biopharma page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.